← boardnext 2026-12next 2032-07
PCRX
Pacira Pharmaceuticals, Incdistress 2/10 · well-funded / low risk$25.33-1%today-7% from 52w high
Lead: Osteoarthritis (OA) of the Knee
Revenue
$177M
Liquidity
$202M
Runway
—
Shares 1y
-12%
Price & events
+22.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-1.1%
1W
+7.7%
1M
-0.1%
3M
+22.5%
6M
+13.8%
1Y
+26.8%
2Y
-56.8%
5Y
-57.3%
All
Overview
- Market Cap
- $996.68M
- Enterprise Value
- $1.22B
- Volume
- 20.27K
- 52 Week Range
- $19.16 – $27.22
- Total Shares
- 39.35M
- Float Shares
- 33.71M
- Short %
- 24.21%
- % Held by Insiders
- 1.77%
- % Held by Institutions
- 115.38%
- RVOL
- 0.04x
- Beta
- 0.27
Pipeline stages · 3 programs
ZILRETTA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Enekinragene Inzadenovec (PCRX-201)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Liposomal Bupivacaine 13.3, Bupivacaine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | ZILRETTA | Glenohumeral Osteoarthritis | — | active not recruiting |
| 2032-07 Estimated 50% readout ~2032-08-15 | Phase 2 | Enekinragene Inzadenovec (PCRX-201) | Osteoarthritis (OA) of the Knee | — | active not recruiting |
| 2025-02-27 | Phase 1 | Liposomal Bupivacaine 13.3, Bupivacaine | Healthy | 54 | completed |
Catalyst news & presentations · 3
- 2026-08-04earningsEarningsEarnings releaseyahoo
- 2026-06-28partnershipiovera · Pacira divests iovera handheld cryoanalgesia devices and related assets to Zimmer Biomet for up to $140M, including $70M upfront and up to $70M in milestones.SEC 8-K
- 2025-04-07partnershipEXPAREL · Settlement agreement granting Fresenius Kabi a license to sell generic bupivacaine liposome injectable suspension in the U.S. starting on confidential dates in early 2030 (volume-limited) and 2039 (unlimited); Pacira to pay $7 million.SEC 8-K
Approved drugs (4)
- ZILRETTATRIAMCINOLONE ACETONIDE2017 · Prescription
- EXPARELBUPIVACAINE2011 · Prescription
- DEPODURMORPHINE SULFATE2004 · Discontinued
- DEPOCYTCYTARABINE1999 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $30 (+17% upside) · 6 analysts
- 2026-07-01HC Wainwright & Co.Buy
- 2026-05-01RBC CapitalSector Perform
- 2026-05-01NeedhamBuy
- 2026-03-26BarclaysEqual-Weight
- 2026-01-09HC Wainwright & Co.Buy
- 2026-01-09NeedhamBuy
Competitors — Osteoarthritis (OA) of the Knee
- none identified
Recent news
- 2026-07-22Pacira stock trades steady as investors weigh Exparel growth and margin trends - Ad-hoc-news.de
- 2026-07-22Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 - GlobeNewswire
- 2026-07-22Pacira will pair Aug. 4 results with a live investor Q&A - Stock Titan
- 2026-07-21Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring A Potential 17% Upside - DirectorsTalk Interviews
- 2026-07-20Understanding the Setup: (PCRX) and Scalable Risk - Stock Traders Daily
- 2026-07-19Pacira stock trades steady as investors weigh Q1 2026 revenue and margin trends - Ad-hoc-news.de
- 2026-07-16Pacira BioSciences stock trades steady as Exparel revenue supports valuation - Ad-hoc-news.de
- 2026-07-09Pacira BioSciences stock trades steady as pain-management pipeline stays in focus - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.